Dyadic to Showcase Disruptive C1 Technology at World Vaccine Congress Europe Announcing Influenza Pipeline Expansion with Improved Efficacy Potential

0

Dyadic International, Inc.

JUPITER, Fla., Oct. 04, 2022 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on creating innovative microbial platforms to treat growing demand for global protein production and unmet clinical needs for effective and affordable biopharmaceuticals for human and animal health, announced today that its Chief Executive Officer, Mark Emalfarb, will present at the upcoming World Vaccine Congress in Barcelona, ​​Spain.

The presentation will highlight significant accomplishments, including:

  • Successful expression of Omicron BA.5 RBD and gRBD ferritin nanoparticle antigens including Wuhan and Omicron BA.2 from C1 cells. Nanoparticle antigens have demonstrated the potential to lead to broader and longer-lasting protection against a number of viruses, including the concerning variants of Covid-19.

  • Improved influenza vaccine efficacy potential and C1-expressed antigen productivity data, expanding our pipeline to help address seasonal and pandemic influenza markets.

  • Continue to demonstrate the benefits of C1 in reducing antigen production costs in the price-sensitive livestock vaccine market through achieving 10 grams per liter of antigen production.

Dr. Emalfarb will also be joined by Dr. Albert Osterhaus from the University of Veterinary Medicine Hannover, who has been collaborating with Dyadic for over 5 years and has conducted preclinical studies on proteins produced from the Cellular Protein Production Platform. C1 from Dyadic, including a non-human primate study of a Covid-19 monoclonal antibody and a rabies antigen.

World Vaccine Congress Europe
October 11-14, 2022
Palau de Congressos de Barcelona (Fira Barcelona – Montjuïc), Barcelona, ​​Spain
Presenters: Mark Emalfarb and Dr. Albert Osterhaus
Presentation title: Alternative production systems: development of a filamentous fungal system for influenza, corona virus and rabies
Presentation time: Thursday, October 13, 2022, 2:45 p.m. to 3:15 p.m. CEST
Registration link: World Vaccine Congress Europe

Please visit us at booth #35 or join us for our poster session during the event. Dyadic leadership will be available during the event for one-on-one meetings. Interested parties may also request a one-on-one meeting at [email protected] or contact Dyadic at (561) 743-8333.

About Dyadic International, Inc.

Dyadic International, Inc. is a global biotechnology company committed to building disruptive microbial platforms to meet the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceuticals for human and animal health. .

Dyadic’s gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Our flagship technology, the C1 Cellular Protein Production Platform, is based on an industrially proven microorganism (called C1), which is currently used to accelerate development, reduce production costs and improve the performance of vaccines and biological drugs. at human-flexible commercial scales. and animal health markets. Dyadic has also developed the Dapibus™ filamentous fungi-based microbial protein production platform to enable rapid development and large-scale manufacturing of low-cost proteins, metabolites and other biologics for non-food applications. pharmaceuticals, such as food, nutrition, and wellness.

With a passion for enabling our partners and collaborators to develop effective preventive and therapeutic treatments in developed and emerging countries, Dyadic is building an active pipeline advancing its proprietary microbial platform technologies, including our lead active vaccine candidate DYAI-100 Covid-19, as well as other biological vaccines, antibodies and other biological products.

To learn more about Dyadic and our commitment to help bring vaccines and other biologics to market faster, in greater volumes and at lower cost, please visit http://www.dyadic.com.

Safe Harbor Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic’s expectations, intentions, strategies and beliefs. International regarding future events or financial performance, such as the success of our clinical trial application and our ability to enter into commercial agreements and take advantage of other commercial opportunities. Actual events or results may differ materially from those in the forward-looking statements due to a variety of important factors, including those described in the Company’s most recent filings with the SEC. Dyadic undertakes no obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section titled “Risk Factors” in Dyadic’s Annual Reports on Form 10-K and Quarterly Reports on Form 10. -Q filed with the SEC, as such factors may be updated from time to time in Dyadic’s periodic filings with the SEC, which are accessible on the SEC’s website and at http:// www.dyadic.com.

Contact:

Dyadic International, Inc.
Ping W. Rawson
Financial director
Telephone: (561) 743-8333
Email: [email protected]

Share.

About Author

Comments are closed.